The drug, a molecule known as TRV027, is set to be trialed in 60 patients with confirmed or suspected infection in hospitals in the United Kingdom, according to a release.
The trial, supported and funded by the British Heart Foundation Centre of Research Excellence at Imperial College London, will follow patients for eight days during the period of intensive care, often when they are on a ventilator.
CCP Virus Impact HormonesResearches say the CCP virus impacts two hormones—angiotensin II and angiotensin 1-7—and the balance between these two affects the blood vessels and blood pressure.
The CCP virus, or SARS—CoV-2, impacts angiotensin-converting enzyme 2 (ACE-2), which maintains the balance between these two hormones.
TRV027 is designed to save a patient's life as it opposes angiotensin II activity and mimics angiotensin 1-7 activity, which opposes angiotensin II.
“We need to move away from thinking of Covid-19 as solely a respiratory illness–it also has devastating effects on the rest of the body including the blood vessels and heart," said Dr. Kat Pollock, Senior Clinical Research Fellow in Vaccinology and Honorary Consultant at Imperial College London.
Pollock, who is one of the two leading the study, said that people with heart and circulatory diseases are more at risk of CCP virus infection and that the research will help find potential treatment.
The researchers said that if the pilot study gives promising results, they will secure funding to conduct a bigger clinical trial.
“This virus poses a huge challenge for researchers because so much about it is unknown. In order to fight it, we need a team effort. This project has brought together pathologists, virologists, pharmacologists, and researchers who usually focus on the heart and circulatory diseases," said Dr. David Owen, Senior Clinical Research Fellow and Clinical Pharmacologist at Imperial College London.
"Drawing on this range of expertise will give us the best chance of finding a desperately needed treatment for Covid-19,” said Owen who is the second lead of the study.